New drug cocktail before radiation shows promise against rectal cancer
NCT ID NCT04503694
First seen Mar 30, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tests whether giving two drugs (nivolumab and regorafenib) before and after a short course of radiation can shrink tumors in people with stage II or III rectal cancer. About 72 participants will receive the treatment, then either have surgery or be closely watched if the cancer disappears. The goal is to see how many patients have no cancer left after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Groeninge
Kortrijk, 8500, Belgium
-
CHR Namur
Namur, 5000, Belgium
-
CHU Ambroise Paré
Mons, 7000, Belgium
-
Chirec Delta
Brussels, 1160, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Grand Hopital de Charleroi
Gilly, 6060, Belgium
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
UZ Gent
Ghent, 9000, Belgium
-
UZAntwerpen
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.